SEARCH WITHIN CONTENT
Citation Information : Immunohematology. Volume 33, Issue 1, Pages 9-14, DOI: https://doi.org/10.21307/immunohematology-2019-003
License : (Transfer of Copyright)
Published Online: 09-October-2019
Alloimmunization to red blood cell antigens is unpredictable and poorly understood. Patients who are negative for highincidence antigens (HIAs) are at risk for developing the corresponding antibodies. Molecular methods can easily predict the lack of an antigen and thus, the risk of an individual to become immunized. We examined the prevalence and risk factors for HIA alloimmunization in patients at risk based on genotyping results. Genotyping using a molecular method (HEA BeadChip™, Immucor, Warren, NJ) was performed on all patient specimens referred for molecular testing over 45 months; serologic and clinical data were analyzed. We used simple and multiple logistic regression to model the risk factors for alloimmunization to an HIA. Of the 2591 patients genotyped, 32 (1.2%) were homozygous for at least one variant predicting absence of an HIA. Of these 32 patients, prior transfusion or pregnancy history was available for 29 (91%). Four susceptible patients made an antibody to an HIA (12.5% of all, 13.8% of those with a documented exposure). Two of these four patients (50%) had made an alloantibody to another antigen. The odds of forming an antibody to an HIA were not related to the total number of transfusions (p = 0.47), the total number of alloantibodies (p = 0.61), or diagnosis of sickle cell disease (p = 0.77) in simple logistic regression. Adjustment for the other two variables in a multiple logistic regression was also not significant for each variable (p = 0.6, p = 0.7, and p = 0.7, respectively). Although they had a known exposure to alloantigens through transfusion or pregnancy, 86.2 percent of patients (25 of 29) at risk for alloantibody formation to an HIA in fact did not mount an immune response to that antigen. Possible risk factors including the number of transfused units or the total number of alloantibodies made were not predictors of making an alloantibody to an HIA in our sampling. Our results suggest that other patient-specific risk factors for alloimmunization exist.
1. Hashmi G, Shariff T, Seul M, et al. A flexible array format for large-scale, rapid blood group DNA typing. Transfusion 2005;45:680–8.
2. Telen MJ, Rosse WF, Parker CJ, Moulds MK, Moulds JJ. Evidence that several high-frequency human blood group antigens reside on phosphatidylinositol-linked erythrocyte membrane proteins. Blood 1990;75:1404–7.
3. Meny GM, Flickinger C, Marcucci C. The American Rare Donor Program. J Crit Care 2013;28:110.e9–18.
4. Seltsam A, Wagner FF, Salama A, Flegel WA. Antibodies to high-frequency antigens may decrease the quality of transfusion support: an observational study. Transfusion 2003;43:1563–6.
5. Reid ME, Lomas-Francis C, Olsson ML. The blood group antigen factsbook. 3rd ed. San Diego, CA: Academic Press, 2012.
6. Leger RM. In vitro cellular assays and other approaches used to predict the clinical significance of red cell alloantibodies: a review. Immunohematology 2002;18:65–70.
7. Higgins JM, Sloan SR. Stochastic modeling of human RBC alloimmunization: evidence for a distinct population of immunologic responders. Blood 2008;112:2546–53.
8. Karafin MS, Shirey RS, Ness PM, King KE. Antigen-matched red blood cell transfusions for patients with sickle cell disease at The Johns Hopkins Hospital. Immunohematology 2012;28: 3–6.
9. Zimring JC, Welniak L, Semple JW, et al. Current problems and future directions of transfusion-induced alloimmunization: summary of an NHLBI working group. Transfusion 2011;51:435–41.
10. Price CL, Johnson MT, Lindsay T, Dalton D, Watkins AR, DeBaun MR. The Sickle Cell Sabbath: a community program increases first-time blood donors in the African American faith community. Transfusion 2009;49:519–23.
11. Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 1990;322:1617–21.
12. Urbaniak SJ. Alloimmunity to human red blood cell antigens. Vox Sang 2002;83(Suppl 1):293–7.
13. Tormey CA, Stack G. Immunogenicity of blood group antigens: a mathematical model corrected for antibody evanescence with exclusion of naturally occurring and pregnancy-related antibodies. Blood 2009;114:4279–82.
14. Zalpuri S, Middelburg RA, Schonewille H, et al. Intensive red blood cell transfusions and risk of alloimmunization. Transfusion 2014;54:278–84.
15. Zalpuri S, Zwaginga JJ, le Cessie S, Elshuis J, Schonewille H, van der Bom JG. Red-blood-cell alloimmunization and number of red-blood-cell transfusions. Vox Sang 2012;102:144–9.
16. Zalpuri S, Evers D, Zwaginga JJ, et al. Immunosuppressants and alloimmunization against red blood cell transfusions. Transfusion 2014;54:1981–7.
17. Giblett ER. A critique of the theoretical hazard of inter vs. intraracial transfusion. Transfusion 1961;1:233–8.